Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Fineline Cube Jan 14, 2026
Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Fineline Cube Jan 14, 2026
Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Fineline Cube Jan 14, 2026
Company Deals

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases

Fineline Cube Jan 14, 2026
Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Fineline Cube Jan 14, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Fineline Cube Jan 14, 2026
Company Drug

Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors

Fineline Cube Jan 14, 2026
Company Drug

HanX Biopharmaceuticals Secures NMPA Approval for HX044‑HX008 PD‑1 Therapy Combination in Advanced Solid Tumors

Fineline Cube Sep 29, 2025

HanX Biopharmaceuticals (Wuhan) Co., Ltd., a fast‑growing Chinese biotech, announced that the National Medical Products...

Company Deals Drug

Novatim Partners with VRise to Launch KQ‑2003 CAR‑T in India

Fineline Cube Sep 29, 2025

Novatim Immune Therapeutics (Zhejiang) Co., Ltd., a leading Chinese cancer‑immunotherapy firm, announced an exclusive licensing...

Company Drug

CMS Announces Phase 3 Success of Ruxolitinib Cream in Atopic Dermatitis

Fineline Cube Sep 28, 2025

China Medical System Holdings Limited (CMS, HKG: 0867) reported that its Phase 3, randomized, double‑blind, placebo‑controlled...

Company

Merck Names Kai Beckmann as Incoming CEO, Signals Smooth Leadership Transition

Fineline Cube Sep 28, 2025

Merck KGaA (ETR: MRK) announced that Kai Beckmann will assume the roles of Chair of...

Policy / Regulatory

Trump’s New Pharmaceutical Tariffs Will Be Limited to 15% for EU and Japan, White House Says

Fineline Cube Sep 28, 2025

A White House spokesperson clarified that President Donald Trump’s proposed tariffs on imported pharmaceuticals will not...

Company Digital

Beijing Unicet’s QH104A Receives Chinese NMPA Approval for CNS Solid‑Tumor Clinical Trials

Fineline Cube Sep 28, 2025

Beijing Unicet Biotechnology Co., Ltd. announced that its pioneering QH104A—the world’s first B7H3‑targeted, off‑the‑shelf allogeneic...

Company Deals

Wolters Kluwer and the Chinese Academy of Medical Sciences Sign AI‑Driven Medical‑Information Collaboration

Fineline Cube Sep 28, 2025

Wolters Kluwer announced a preliminary collaboration agreement with the Institute of Medical Information of the...

Drug

Leo Pharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor

Fineline Cube Sep 28, 2025

Denmark-based dermatology specialist LEO Pharma A/S announced that the Greater Bay Area’s first prescription of...

Company Deals

Shanghai MicuRx and GenScript’s ProBio Unit Sign Strategic Deal to Accelerate Antibody‑Drug Conjugate (ADC) Development

Fineline Cube Sep 28, 2025

Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA: 688373) and Nanjing ProBio, a subsidiary of GenScript Biotech...

Policy / Regulatory

NHSA Launches 100‑Day Medical‑Insurance Fraud Crackdown Campaign

Fineline Cube Sep 26, 2025

The National Healthcare Security Administration (NHSA) announced a nationwide 100‑Day Action aimed at eradicating illegal...

Company Drug

CSPC Pharma Secures NMPA Approval for Lecanemab Biosimilar, First of Its Kind in China

Fineline Cube Sep 26, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Trump Announces 100% Tariff on Branded Drugs, Exempts U.S.‑Built Pharmaceutical Factories

Fineline Cube Sep 26, 2025

President Donald J. Trump announced via a social‑media post that the United States will impose a 100 % tariff...

Policy / Regulatory

China Unveils National Long‑Term Care Insurance Service Catalog in Pilot Phase

Fineline Cube Sep 26, 2025

The National Healthcare Security Administration (NHSA) released the National Long‑Term Care Insurance Service Catalog (Trial),...

Company Drug

Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma

Fineline Cube Sep 26, 2025

China‑based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the Center for Drug...

Company Drug Policy / Regulatory

Fosun Pharma’s Alovatinib Enters China’s Pediatric Anti‑Tumor SPARK Pilot

Fineline Cube Sep 26, 2025

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that...

Company Drug

Eli Lilly Halts Obesity Study of Experimental Drug Bimagrumab for Strategic Reasons

Fineline Cube Sep 26, 2025

Eli Lilly & Co. (NYSE: LLY) announced that it has discontinued a phase I/II trial of...

Company Deals

Sanofi Injects an Extra USD 625 Million into Sanofi Ventures to Boost Biotech & Digital‑Health Innovation

Fineline Cube Sep 25, 2025

Sanofi (NASDAQ: SNY) announced today a new capital infusion of USD 625 million into its corporate venture...

Company Deals

Illumina Partners with Pharma Giants on Pan‑Cancer Companion Diagnostics Using TruSight Oncology

Fineline Cube Sep 25, 2025

Illumina Inc. (NASDAQ: ILMN) announced a new alliance with a group of global pharmaceutical companies...

Company Drug

AstraZeneca and Daiichi Sankyo Submit Priority‑Review sBLA for Enhertu as First‑Line Therapy for HER2‑Positive Breast Cancer

Fineline Cube Sep 25, 2025

AstraZeneca (AZ; NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have filed a supplemental Biologics License...

Company Deals

Gan & Lee Secures 3 B RMB Supply Deal for Insulin Glargine in Brazil’s National PDP

Fineline Cube Sep 25, 2025

Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) announced a landmark Technology Transfer and Supply...

Posts pagination

1 … 41 42 43 … 609

Recent updates

  • NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development
  • AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D
  • Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund
  • WuXi AppTec Projects 2025 Revenue of $6.51 Billion, Net Profit Surges 103% on Divestments
  • Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Company

WuXi AppTec Projects 2025 Revenue of $6.51 Billion, Net Profit Surges 103% on Divestments

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.